New Delhi, Sep 26, 2025

India’s pharmaceutical sector, which mainly exports cheaper generic drugs to the US market, is not expected to be significantly affected by President Donald Trump’s imposition of 100 per cent import tariffs on branded or patented pharmaceutical drugs from October 1.

The hike in US tariffs mainly targets branded and patented drugs, exported by multinational pharma giants such as Pfizer and Novo Nordisk. The increase in the import tariff comes in the backdrop of Trump’s severe criticism of big pharma companies for the high prices they are charging in the US market.

Indian generic drugs, on the other hand, are cheaper substitutes for these branded drugs in treating diseases ranging from cancer to diabetes and help to keep the cost of medicines within the affordable

See Full Page